<DOC>
	<DOC>NCT02273856</DOC>
	<brief_summary>The purpose of this study is to document the pharmacological treatment strategies used in treatment na√Øve and previously treated relapsed/refractory iNHL/CLL patients in the Middle East and North African (MENA) region. This study will also record encountered tumor subtype and stage and the instituted pharmacological treatments, as well as assess the clinical outcomes of treatments.</brief_summary>
	<brief_title>Multicentre Registry of Treatments and Outcomes in Patients With Chronic Lymphocytic Leukaemia (CLL) Or Indolent Non Hodgkin's Lymphoma (iNHL)</brief_title>
	<detailed_description>Patients will be followed up to 30 months.</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
	<mesh_term>Leukemia, Lymphoid</mesh_term>
	<mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
	<criteria>Informed consent CLL patients or iNHL patients Clinical decision made to initiate or adapt treatment of CLL/iNHL("Need to treat") Patient deemed unfit for enrollment by the documented opinion of the investigator Watch and wait patients Richter's transformation Patients otherwise not eligible for (pharmacological) intervention Moribund patients</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Chronic Lymphocytic Leukaemia (CLL)</keyword>
	<keyword>Indolent Non Hodgkin's Lymphoma (iNHL)</keyword>
</DOC>